CD22 and systemic lupus erythematosus: For example, epratuzumab, which targets CD22 expressed on developing B cells, except plasma cells and plasmablasts, showed no difference in effectiveness from the standard treatment in phase III clinical trials in patients with systemic lupus erythematosus (46–48).